De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma

Clinical and Experimental Immunology

Volumn 125, Issue 1, 2001, Pages 3-9

  Zhang, J Y ^a   Zhu, W ^a   Imai, H ^b   Kiyosawa, K ^b   Chan, E K L ^a   Tan, E M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer antigens; Cancer autoimmunity; CENP F; Hepatocellular carcinoma; p62

Indexed keywords

AUTOANTIGEN; COMPLEMENTARY DNA; PROTEIN CENP F; PROTEIN P62; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CELL CYCLE; CHRONIC LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; CARCINOMA, HEPATOCELLULAR; CHROMOSOMAL PROTEINS, NON-HISTONE; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; RNA-BINDING PROTEINS;

EID: 0034905974     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01585.x     Document Type: Article

References (55)

1. Hepatitis B virus, the vaccine, and the control of primary cancer of the liver
2. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
3. Hepatocellular carcinoma. A worldwide problem and the major risk factors
4. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan China
5. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma
6. Novel nuclear antoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma
7. Autoantibodies in pathology and cell biology
8. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity
9. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB × NZW) F1 mice
10. Genetic and structural evidence for antigen selection of anti-DNA antibodies
11. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis
12. CENP-F is a ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization
13. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells
14. SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain
15. WD40 repeat proteins striatin and S/G (2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A
16. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma
17. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development
18. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein
19. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
20. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas
21. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients
22. New paths in human cancer serology
23. Human neoplasms elicit multiple specific immune responses in the autologous host
24. The multistep nature of cancer
25. p53, the cellular gatekeeper for growth and division
26. The hallmarks of cancer
27. Autoantibodies in diagnosis and in identifying autoantigens
28. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F
29. Autoantibodies to ribonucleoprotein particles by immunoblotting
30. A comprehensive set of sequence analysis programs for the VAX
31. On global sequence alignment
32. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation
33. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers
34. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: A population-based epidemiological study
35. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma
36. Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations
37. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer
38. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer
39. Messenger ribonucleoprotein complexes containing human ELAV proteins: Interactions with cytoskeleton and translational apparatus
40. Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology
41. The importance of defining the paraneoplastic neurologic disorders
42. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors
43. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies
44. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library
45. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
46. Oncogenic proteins as tumor antigens
47. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies
48. Diversity of antinuclear antibody responses in hepatocellular carcinoma
49. RNA recognition: Towards identifying determinants of specificity
50. Conserved structures and diversity of functions of RNA-binding proteins
51. The c-myc coding region determinant-binding protein: A member of a family of KH domain RNA-binding proteins
52. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro
53. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis
54. Insulin-like growth factor II mRNA expression in human breast cancer
55. Transcripts of the insulin-like growth factors I and II in human hepatoma